JoinClinicalTrials.com

Results

Hot

Post your clinical trial on JoinClinicalTrials.com

Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

• Safety Follow-up Study in Subjects With Silicone Gel-filled Breast Implants as Compared Both to Saline-filled Breast Implants and to National Norms

  NCT00443274

  Condition:   Breast Implant
  Interventions:   Other: NBIR Placeholder;   Device: 410 Arm;   Device: BIFs
  Sponsor:   Allergan
  Recruiting
• Addressing Dementia Via Agitation-Centered Evaluation

  NCT03226522

  Conditions:   Agitation in Patients With Dementia of the Alzheimer's Type;   Alzheimer Disease;   Agitation,Psychomotor
  Interventions:   Drug: AXS-05;   Drug: Bupropion;   Drug: Placebo
  Sponsor:   Axsome Therapeutics, Inc.
  Recruiting
• Ambulatory Post-Syncope Arrhythmia Protection Feasibility Study

  NCT02188147

  Condition:   Syncope
  Intervention:   Device: Short Term Wearable Defibrillator
  Sponsor:   Zoll Medical Corporation
  Recruiting
• Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder

  NCT04044664

  Condition:   Post-Traumatic Stress Disorder
  Interventions:   Drug: Placebo oral capsule;   Drug: NYX-783
  Sponsors:   Aptinyx;   Premier Research Group plc;   Massachusetts General Hospital
  Recruiting
• Randomized Trial of Adult Subjects With Generalized Anxiety Disorder

  NCT03829241

  Condition:   Generalized Anxiety Disorder
  Interventions:   Drug: Troriluzole;   Drug: Placebo
  Sponsor:   Biohaven Pharmaceuticals, Inc.
  Recruiting
• Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors

  NCT03662204

  Conditions:   Breast Cancer;   Lung Cancer;   Colorectal Cancer;   Prostate Cancer;   Bladder Cancer;   Uterine Cancer;   Kidney Cancer;   Renal Pelvis Cancer;   Pancreatic Cancer;   Liver Cancer;   Stomach Cancer;   Ovarian Cancer;   Esophageal Cancer
  Intervention:   Other: Blood Sample Collection
  Sponsor:   Exact Sciences Corporation
  Recruiting
• Prospective Assessment of Premature Ventricular Contractions Suppression in Cardiomyopathy(PAPS)

  NCT03228823

  Conditions:   Ventricular Premature Beats, Contractions, or Systoles;   Cardiomyopathies
  Interventions:   Procedure: Radiofrequency ablation;   Drug: Amiodarone (Antiarrhythmic drug)
  Sponsors:   Hunter Holmes Mcguire Veteran Affairs Medical Center;   Virginia Commonwealth University;   University of California, San Francisco;   University of Calgary;   Washington University School of Medicine;   Wake Forest University Health Sciences;   National Heart, Lung, and Blood Institute (NHLBI)
  Recruiting
• A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension

  NCT03504917

  Condition:   Autism Spectrum Disorder
  Interventions:   Drug: Balovaptan;   Drug: Placebo
  Sponsor:   Hoffmann-La Roche
  Recruiting
• Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease

  NCT03486938

  Conditions:   Mild Cognitive Impairment;   Prodromal Alzheimer's Disease
  Interventions:   Drug: Placebo Oral Tablet;   Drug: AGB101 220 mg tablet
  Sponsors:   AgeneBio;   National Institute on Aging (NIA)
  Recruiting
• Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

  NCT03473223

  Condition:   Acute Coronary Syndrome
  Interventions:   Biological: Apolipoprotein A-I [human] (apoA-I);   Other: Placebo
  Sponsor:   CSL Behring
  Recruiting
• Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

  NCT03443973

  Condition:   Alzheimer's Disease
  Interventions:   Drug: Gantenerumab;   Drug: Placebo
  Sponsor:   Hoffmann-La Roche
  Recruiting
• Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer

  NCT03414970

  Conditions:   Ductal Breast Carcinoma;   Invasive Breast Carcinoma;   Lobular Breast Carcinoma;   Medullary Breast Carcinoma;   Stage II Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Tubular Breast Carcinoma
  Interventions:   Radiation: Radiation Therapy;   Other: Questionnaire Administration;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis;   Radiation: Hypofractionated Radiation Therapy
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Canadian Cancer Trials Group
  Recruiting
• Phase 3 Study of Reltecimod vs Placebo in Patients With Sepsis-associated Acute Kidney Injury

  NCT03403751

  Conditions:   Acute Kidney Injury;   Peritonitis;   Necrotizing Soft Tissue Infection
  Interventions:   Drug: Reltecimod;   Drug: 0.9% Sodium Chloride Injection
  Sponsor:   Atox Bio Ltd
  Recruiting
• Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE)

  NCT03373045

  Condition:   Asthma
  Intervention:  
  Sponsors:   AstraZeneca;   Parexel;   MedImmune LLC
  Recruiting
• A Study of the Efficacy and Safety of Upadacitnib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies

  NCT03345849

  Condition:   Crohn's Disease
  Interventions:   Drug: Upadacitinib;   Drug: Placebo for Upadacitinib
  Sponsor:   AbbVie
  Recruiting
• A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy

  NCT03345836

  Condition:   Crohn's Disease
  Interventions:   Other: Matching placebo for upadacitinib;   Drug: upadacitinib
  Sponsor:   AbbVie
  Recruiting
• Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis

  NCT03325556

  Condition:   Dementia-related Psychosis
  Interventions:   Drug: Placebo;   Drug: Pimavanserin 34 mg;   Drug: Pimavanserin 20 mg
  Sponsor:   ACADIA Pharmaceuticals Inc.
  Recruiting
• BHV-4157 in Adult Subjects With Obsessive Compulsive Disorder

  NCT03299166

  Condition:   Obsessive-Compulsive Disorder
  Interventions:   Drug: BHV-4157;   Drug: Placebo
  Sponsor:   Biohaven Pharmaceuticals, Inc.
  Recruiting
• Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy (The C-TRACT Trial)

  NCT03250247

  Conditions:   Deep Vein Thrombosis;   Venous Stasis;   Venous Insufficiency;   Venous Leg Ulcer;   Venous Reflux;   Post Thrombotic Syndrome
  Intervention:   Device: Stents
  Sponsors:   Washington University School of Medicine;   Ontario Clinical Oncology Group (OCOG) - McMaster University;   VasCore - Massachusetts General Hospital;   Mid America Heart Institute - St. Luke's Hospital
  Recruiting
• Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids

  NCT03070899

  Conditions:   Uterine Fibroids;   Heavy Menstrual Bleeding
  Interventions:   Drug: Placebo + Placebo Add-back;   Drug: OBE2109 + Placebo Add-back;   Drug: OBE2109 + Add-back
  Sponsor:   ObsEva SA
  Recruiting
• A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression

  NCT03044249

  Conditions:   Psychosis;   Dementia;   Aggression;   Agitation;   Alzheimer Dementia
  Interventions:   Drug: MP-101;   Drug: Placebo
  Sponsor:   Mediti Pharma Inc.
  Recruiting
• Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency

  NCT03037931

  Conditions:   Heart Failure;   Iron-deficiency
  Interventions:   Drug: Ferric carboxymaltose;   Drug: Placebos
  Sponsors:   American Regent, Inc.;   Duke Clinical Research Institute
  Recruiting
• Myocardial Ischemia and Transfusion

  NCT02981407

  Conditions:   Myocardial Infarction;   Anemia
  Intervention:   Biological: Red Blood Cell Transfusion
  Sponsors:   Rutgers, The State University of New Jersey;   University of Pittsburgh;   National Heart, Lung, and Blood Institute (NHLBI)
  Recruiting
• Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer

  NCT02954874

  Conditions:   Estrogen Receptor Negative;   HER2/Neu Negative;   Invasive Breast Carcinoma;   Progesterone Receptor Negative;   Stage 0 Breast Cancer AJCC v6 and v7;   Stage I Breast Cancer AJCC v7;   Stage IA Breast Cancer AJCC v7;   Stage IB Breast Cancer AJCC v7;   Stage II Breast Cancer AJCC v6 and v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Triple-Negative Breast Carcinoma
  Interventions:   Other: Laboratory Biomarker Analysis;   Other: Patient Observation;   Biological: Pembrolizumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radiation Therapy
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation

  NCT02928497

  Condition:   Stroke
  Interventions:   Device: WATCHMAN LAAC Device Implant;   Drug: Single Antiplatelet Therapy or No Therapy (Control)
  Sponsor:   Boston Scientific Corporation
  Recruiting
• Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy

  NCT02927249

  Condition:   Node Positive HER2 Negative Breast Cancer
  Interventions:   Other: Placebo;   Drug: Aspirin
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   United States Department of Defense;   Bayer;   Canadian Cancer Trials Group
  Recruiting
• Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer

  NCT02921256

  Conditions:   Rectal Adenocarcinoma;   Stage II Rectal Cancer AJCC v7;   Stage III Rectal Cancer AJCC v7
  Interventions:   Drug: Capecitabine;   Drug: Fluorouracil;   Radiation: Intensity-Modulated Radiation Therapy;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Biological: Pembrolizumab;   Drug: Veliparib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression

  NCT02782104

  Condition:   Depressive Disorder, Treatment-Resistant
  Intervention:   Drug: Esketamine Nasal Spray
  Sponsor:   Janssen Research & Development, LLC
  Recruiting
• Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Treating Patients With Limited Stage or Extensive Stage Small Cell Lung Cancer

  NCT02635009

  Conditions:   Extensive Stage Small Cell Lung Carcinoma;   Limited Stage Small Cell Lung Carcinoma
  Interventions:   Radiation: 3-Dimensional Conformal Radiation Therapy;   Other: Cognitive Assessment;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI);   Radiation Therapy Oncology Group
  Recruiting
• Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)

  NCT02595944

  Conditions:   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7
  Intervention:   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension

  NCT02586623

  Condition:   Symptomatic Neurogenic Orthostatic Hypotension
  Interventions:   Drug: Droxidopa capsules;   Drug: Placebo capsules
  Sponsor:   Lundbeck Northera Ltd.
  Recruiting
• Assessment of the GORE® EXCLUDER® Conformable AAA Endoprosthesis in the Treatment of Abdominal Aortic Aneurysms

  NCT02489539

  Condition:   Aortic Aneurysm, Abdominal
  Intervention:   Device: GORE® EXCLUDER® Conformable AAA Endoprosthesis
  Sponsor:   W.L.Gore & Associates
  Recruiting
• Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

  NCT02488967

  Conditions:   Breast Adenocarcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
  Interventions:   Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Recruiting
• Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

  NCT02446132

  Condition:   Agitation in Patients With Dementia of the Alzheimer's Type
  Intervention:   Drug: AVP-786
  Sponsor:   Avanir Pharmaceuticals
  Recruiting
• Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

  NCT02201992

  Conditions:   ALK Gene Rearrangement;   ALK Gene Translocation;   ALK Positive;   Stage IB Non-Small Cell Lung Carcinoma AJCC v7;   Stage II Non-Small Cell Lung Cancer AJCC v7;   Stage IIA Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIB Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIIA Non-Small Cell Lung Cancer AJCC v7
  Interventions:   Other: Clinical Observation;   Drug: Crizotinib;   Other: Laboratory Biomarker Analysis
  Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
  Recruiting
• Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

  NCT02194738

  Conditions:   Lung Adenocarcinoma;   Lung Large Cell Carcinoma;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IB Lung Squamous Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage II Lung Squamous Cell Carcinoma AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIA Lung Squamous Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Squamous Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7;   Stage IIIA Lung Squamous Cell Carcinoma AJCC v7
  Interventions:   Other: Clinical Observation;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Erlotinib Hydrochloride;   Biological: Nivolumab;   Other: Placebo
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

  NCT02193282

  Conditions:   ALK Gene Rearrangement;   EGFR Exon 19 Deletion Mutation;   EGFR NP_005219.2:p.L858R;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7
  Interventions:   Other: Clinical Observation;   Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Best Endovascular vs. Best Surgical Therapy in Patients With Critical Limb Ischemia

  NCT02060630

  Condition:   Critical Limb Ischemia
  Interventions:   Procedure: Open surgical revascularization;   Device: Endovascular revascularization
  Sponsors:   New England Research Institutes;   Brigham and Women's Hospital;   Massachusetts General Hospital;   Boston Medical Center;   National Heart, Lung, and Blood Institute (NHLBI)
  Recruiting
• Psoriasis Longitudinal Assessment and Registry (PSOLAR)

  NCT00508547

  Conditions:   Psoriasis;   Arthritis, Psoriatic
  Interventions:   Biological: Ustekinumab;   Biological: Biological therapies other than infliximab, ustekinumab and guselkumab;   Drug: Conventional systemic agents;   Biological: Infliximab;   Biological: Guselkumab
  Sponsor:   Janssen Scientific Affairs, LLC
  Recruiting
• Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza

  NCT03684044

  Condition:   Influenza
  Interventions:   Drug: Baloxavir Marboxil;   Other: Placebo
  Sponsor:   Hoffmann-La Roche
  Recruiting
• A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT03653026

  Condition:   Ulcerative Colitis (UC)
  Interventions:   Drug: Upadacitinib (ABT-494);   Drug: Placebo
  Sponsor:   AbbVie
  Recruiting
• Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia

  NCT03503318

  Condition:   Schizophrenia
  Interventions:   Drug: TV-46000 - A;   Drug: TV-46000 - B;   Drug: Placebo
  Sponsor:   Teva Branded Pharmaceutical Products, R&D Inc.
  Recruiting
• A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis (UC)

  NCT02819635

  Condition:   Ulcerative Colitis (UC)
  Interventions:   Drug: Placebo;   Drug: Updacitinib (ABT-494)
  Sponsor:   AbbVie
  Recruiting
• A Registry for Patients With Chronic Hypoparathyroidism

  NCT01922440

  Condition:   Chronic Hypoparathyroidism
  Intervention:   Drug: Combination product (Natpara) and drug or supplements [Disease and drug registry]
  Sponsor:   Shire
  Recruiting
• Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

  NCT01442194

  Condition:   Multiple Sclerosis
  Interventions:   Drug: other disease-modifying therapy;   Drug: Fingolimod
  Sponsor:   Novartis Pharmaceuticals
  Recruiting
• Web Based Orthopaedic Sports Medicine Registry

  NCT01191151

  Conditions:   Degenerative and Traumatic Pathology of the Knee;   Degenerative and Traumatic Pathology of the Shoulder and Elbow;   Degenerative and Traumatic Pathology of the Foot and Ankle;   Degenerative and Traumatic Pathology of the Hand and Wrist;   Degenerative and Traumatic Pathology of the Hip
  Intervention:  
  Sponsor:   Arthrex, Inc.
  Recruiting